Interim PET in DLBCL : the Swiss experience - International Workshop
Enrollment : complete Recruitment from Swiss centers. Estimated Primary Completion Date:June 2011 (Final data collection date for ... consolidation RTh.
Interim PET in DLBCL : the Swiss experience Luca Ceriani Oncology Institute of Southern Switzerland Bellinzona
Nuclear Medicine Dpt. - PET/CT centre
Interim PET in DLBCL: the Swiss experience Two ongoing studies:
SAKK - Swiss Group for Clinical Cancer Research Trial 38/07 Prospective evaluation of the predictive value of PET in patients with diffuse large B-cell-lymphoma under R-CHOP-14. A multicenter study. Current status : open . Enrollment : complete Recruitment from Swiss centers Estimated Primary Completion Date:June 2011 (Final data collection date for primary outcome measure)
IELSG - International Extranodal Lymphoma Study Group Trial 26 A clinico-pathologic study of Primary Mediastinal B-cell lymphoma Current Status: open Enrollement : complete Recruitment from International centers Estimate closure Date 31/05/2010
Nuclear Medicine Dpt. - PET/CT centre
Interim PET in DLBCL: the Swiss experience
SAKK - Swiss Group for Clinical Cancer Research Trial 38/07 Prospective evaluation of the predictive value of PET in patients with diffuse large Bcell-lymphoma under R-CHOP-14. A multicenter study. OBJECTIVE:
To evaluate if an early positive positron emission tomography (PET) scan after 2 courses of R-CHOP 14 can be used to identify a group of patients having a poor prognosis.
Nuclear Medicine Dpt. - PET/CT centre
SAKK- 38-07 Baseline PETCT
Interim PET-CT after 2 cycles
Interim PET-CT after 4 cycles
Final PET-CT (3-4 weeks after ChT)
Nuclear Medicine Dpt. - PET/CT centre
SAKK- 38-07 Preliminary Results interim PET positivity after the 2nd R-CHOP14 cycle (n=76/ 156) • Definition:
max Uptake > max bloodpool + 15%
(%)
By the courtesy of Dr. Ch. Mamot - Aarau Nuclear Medicine Dpt. - PET/CT centre
Interim PET in DLBCL: the Swiss experience
IELSG - International Extranodal Lymphoma Study Group Trial 26 A clinico-pathologic study of Primary Mediastinal B-cell lymphoma
MAIN OBJECTIVE:
To obtain data on PET-CT response rate at the end of treatment in the R-chemo era, prior to design a sub-sequent randomized trial of consolidation RTh Interim PET (not reimbursed by health insurances in several countries at the time the study was designed) was not mandatory
Nuclear Medicine Dpt. - PET/CT centre
IELSG- 26 Pts with primary mediastinal DLBCL Registration for trial - central review of pathology Full staging
Baseline PET (within 14 days before Cht)
Full course of chemotherapy: (after half of planned Cht )
R-CHOP 21 R-CHOP 14 R-MACOP - B R-VACOP - B R-ACVBP
Final PET
Restaging
Interim PET (*)
(*) suggested, not mandatory
(3-4 weeks after ChT)
Consolidation radiotherapy according to local protocol post RTh - PET
Follow-up
(at least 2 months after RTh)
Nuclear Medicine Dpt. - PET/CT centre
IELSG 26 Preliminary data - PET local interpretation •
Criteria for PET (-):
Baseline
Visual analysis negative or SUV max target lesion < SUV max blood pool aorta
45 PET +
% Positive (95% C.I.)
Interim
24 PET +
21 PET -
53%
(38-68)
Final
17 PET +
28 PET -
38%
(24-53)
7 PET +
38 PET -
16%
(6-29)
post RTh
Nuclear Medicine Dpt. - PET/CT centre
IELSG 26 Preliminary data - PET local interpretation
if + (scores 4-5) or equivocal (score 3) then PET after 2 ABVD cycle. ⢠N=199 HL. 54 I-IIA .... Baseline MTV predictive of PFS and OS although tumor bulk was not.
Predictive value of interim PET. Focus on ... X. Kostakoglu. J Nucl Med 2002. 30 ... Curability. PET is more than just an image ... Which level ( 4/5, âSUV value)?.
Apr 8, 2010 - Positivity/Reference background. â¢Nearby background. â¢Mediastinal blood pool ... On which curve is this patient? Significance of minimal ...
A 110 - Mounier N, Bower M, Spina M, Besson C, Schiantarelli C, Re A Bonnet F ..... Medicine Unit, Ospedale Policlinico, Padova; (7) Nuclear Medicine Unit, Ospedale La ...... Results: The average (median) time per scan upload and download.
Apr 8, 2010 - PET-positive after two courses of. ABVD and comparison of RT on prior bulk versus no RT in PET-negative patients at the end of chemotherapy.
Second international workshop on interim-PET in lymphoma. Menton (France), Palais de l'Europe, April 8-9th, 2010. Under the auspices of GELA, IIL, EORTC, ...
Sep 25, 2011 - lymphoma, new radiotracers and new imaging modalities. ⢠Evolving drugs: the era of targeted therapy could change the way we use PET ...
Staging and risk assessment of marginal zone lymphoma: ââ¦The value of positron emission ... MALT originating from the left lacrimal gland. PET-CT in MALT ...
VU University Medical Center. Amsterdam The Netherlands ... Fatigue, weight loss and anorexia since 3 months. Physical examination. ⢠Swollen left knee/tibia ...
published in Leukemia Lymphoma. ⢠Would the next step be :Imaging in ... lymphoma subtypes (FL,MCL,T-lymphoma ). 3. Identify key area of research in ...
FDG-PET after 2 cycles appears highly predictive, particularly for ... features (bulk, 3+ sites). ⢠All prognostic ... Assumptions: â 75% PET-negative after 2 ABVD.
Apr 9, 2010 - Haematology Torino and Rome. Second International workshop ... >No concomitant cardiac, liver, lung or renal disease. >HIV negativity, HCV ...
background activity to define PET positivity for a residual mass 2 cm in greatest transverse ... Volumetric analysis of tumour bulk and total tumour burden.
